Lipid-lowering drugs associated with slower motor decline in the elderly adults

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 69 A, Issue 2, 2014, Pages 199-206

  Dumurgier, Julien ^a,b,c   Singh Manoux, Archana ^a,c,d,e   Tavernier, Béatrice ^f   Tzourio, Christophe ^g,h   Elbaz, Alexis ^a,c,e  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f DIJON UNIVERSITY HOSPITAL   (France)

^g INSERM   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Epidemiology; Gait; Lipid lowering drugs; Motor function; Statins

Indexed keywords

FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; EPIDEMIOLOGY.; FEMALE; FRANCE; GAIT; HUMAN; LIPID-LOWERING DRUGS; MALE; MOTOR ACTIVITY; MOTOR PERFORMANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; VERY ELDERLY;

EPIDEMIOLOGY.; GAIT; LIPID-LOWERING DRUGS; MOTOR FUNCTION; STATINS;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FIBRIC ACIDS; FRANCE; GAIT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MOTOR ACTIVITY; TIME FACTORS;

EID: 84896788024     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glt140     Document Type: Article

References (40)

1. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305:50-58.
2. Dumurgier J, Elbaz A, Ducimetière P, Tavernier B, Alpérovitch A, Tzourio C. Slow walking speed and cardiovascular death in well functioning older adults: prospective cohort study. BMJ. 2009;339:b4460.
3. White DK, Neogi T, Nevitt MC, et al. Trajectories of gait speed predict mortality in well-functioning older adults: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci. 2013;68:456-464.
4. Peel NM, Kuys SS, Klein K. Gait speed as a measure in geriatric assessment in clinical settings: a systematic review. J Gerontol A Biol Sci Med Sci. 2013;68:39-46.
5. Dumurgier J, Elbaz A, Dufouil C, Tavernier B, Tzourio C. Hypertension and lower walking speed in the elderly: the Three-City study. J Hypertens. 2010;28:1506-1514.
6. Ko SU, Stenholm S, Chia CW, Simonsick EM, Ferrucci L. Gait pattern alterations in older adults associated with type 2 diabetes in the absence of peripheral neuropathy-results from the Baltimore Longitudinal Study of Aging. Gait Posture. 2011;34:548-552.
7. Verghese J, Holtzer R, Oh-Park M, Derby CA, Lipton RB, Wang C. Infammatory markers and gait speed decline in older adults. J Gerontol A Biol Sci Med Sci. 2011;66:1083-1089.
8. Volpato S, Ble A, Metter EJ, et al. High-density lipoprotein cholesterol and objective measures of lower extremity performance in older nondisabled persons: the InChianti study. J Am Geriatr Soc. 2008;56:621-629.
9. Cesari M, Marzetti E, Laudisio A, et al. Interaction of HDL cholesterol concentrations on the relationship between physical function and infammation in community-dwelling older persons. Age Ageing. 2010;39:74-80.
10. Quist-Paulsen P. Statins and infammation: an update. Curr Opin Cardiol. 2010;25:399-405.
11. Corsonello A, Garasto S, Abbatecola AM, et al. Targeting infammation to slow or delay functional decline: where are we? Biogerontology. 2010;11:603-614.
12. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107:757-761.
13. Giri J, McDermott MM, Greenland P, et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol. 2006;47:998-1004.
14. Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007;55:420-425.
15. Gray SL, Aragaki AK, La Monte MJ, et al. Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc. 2012;60:2206-2214.
16. La Croix AZ, Gray SL, Aragaki A, et al. Women's Health Initiative. Statin use and incident frailty in women aged 65 years or older: prospective fndings from the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci. 2008;63:369-375.
17. The 3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology. 2003;22:316-325.
18. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26:15-19.
19. Ko SU, Stenholm S, Metter EJ, Ferrucci L. Age-associated gait patterns and the role of lower extremity strength - results from the Baltimore Longitudinal Study of Aging. Arch Gerontol Geriatr. 2012;55:474-479.
20. AFSSAPS. Prise en charge thérapeutique du patient dyslipidémique. Recommandations mars 2005. 2005. [French Agency for Medical Safety of Health Products (AFSSAPS). Recommendations on how to deal with patient suffering from dyslipidemia. 2005.]
21. Gray SL, Boudreau RM, Newman AB, et al. Health, Aging and Body Composition Study. Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: the Health, Aging and Body Composition study. J Am Geriatr Soc. 2011;59:2226-2232.
22. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185-197.
23. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508.
24. Landi F, Russo A, Cesari M, Pahor M, Bernabei R, Onder G. HDL-cholesterol and physical performance: results from the ageing and longevity study in the Sirente geographic area (ilSIRENTE Study). Age Ageing. 2007;36:514-520.
25. Cesari M, Penninx BW, Pahor M, et al. Infammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59:242-248.
26. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993-999.
27. Soumaré A, Elbaz A, Zhu Y, et al. White matter lesions volume and motor performances in the elderly. Ann Neurol. 2009;65:706-715.
28. Murray AD, Staff RT, Shenkin SD, Deary IJ, Starr JM, Whalley LJ. Brain white matter hyperintensities: relative importance of vascular risk factors in nondemented elderly people. Radiology. 2005;237:251-257.
29. Mok VC, Lam WW, Fan YH, et al. Effects of statins on the progression of cerebral white matter lesion: post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J Neurol. 2009;256:750-757.
30. Van Der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009;88:64-75.
31. Dolga AM, Granic I, Nijholt IM, et al. Pretreatment with lovastatin prevents N-methyl-D-aspartate-induced neurodegeneration in the magnocellular nucleus basalis and behavioral dysfunction. J Alzheimers Dis. 2009;17:327-336.
32. Tiainen K, Hurme M, Hervonen A, Luukkaala T, Jylhä M. Infammatory markers and physical performance among nonagenarians. J Gerontol A Biol Sci Med Sci. 2010;65:658-663.
33. Skaletz-Rorowski A, Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol. 2003;14:599-603.
34. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol. 2005;60:543-551.
35. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42:1208-1215.
36. Sheppard JP, Singh S, Fletcher K, McManus RJ, Mant J. Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ. 2012;345:e4535.
37. Sabia S, Dumurgier J, Tavernier B, Head J, Tzourio C, Elbaz A. Change in fast walking speed preceding death: Results from a prospective longitudinal cohort study. J Gerontol A Biol Sci Med Sci. 2013. doi:10.1093/gerona/glt114.
38. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166:348-354.
39. Williams JW, Plassman BL, Burke J, Benjamin S. Preventing Alzheimer's disease and cognitive decline. Evid Rep Technol Assess. 2010;193:297.
40. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864-1870.